# US 6,727,241 B2 · Anti-inflammatory compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,241 B2
- Document ID: US6727241B2
- Status: Granted
- Kind: B2
- Application number: 10/171,097
- Filed: 2002-06-12
- Published: 2003-12-25
- Granted: 2004-04-27
- Earliest claimed: 2002-06-12
- Assignees: ChemoCentryx, Inc.
- Inventors: Brian McMaster
- Web page: https://patentgrep.com/patent/US6727241B2

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to pharmaceutical compositions containing active compounds, which inhibit the activity of the chemokines, MIP-1α and RANTES. It also is directed to methods of treating inflammatory and immunoregulatory disorders and diseases using these pharmaceutical compositions.

## Claims

### Claim 1

A composition comprising a pharmaceutically acceptable carrier and a compound of the formula (1):
where:
n is 0, 1, or 2;
Y is oxygen or sulfur;
R1, R2, and R3 are each, independently, hydrogen, alkyl, alkoxy, halogen, haloalkyl or nitro.

### Claim 2 (depends on 1)

The composition of claim 1, wherein compound (3) is a compound of the formula (2):
where:
n is 0, 1, or 2;
Y is oxygen or sulfur; and
R1, R2, and R3 are each, independently, hydrogen, alkyl, alkoxy, halogen, haloalkyl or nitro.

### Claim 3 (depends on 1)

The composition of claim 1, wherein R1 and R2 are hydrogen.

### Claim 4 (depends on 1)

The composition of claim 1, wherein R3 is halogen.

### Claim 5 (depends on 4)

The composition of claim 4, wherein R3 is chlorine or fluorine.

### Claim 6 (depends on 1)

The composition of claim 1, wherein R3 is hydrogen.

### Claim 7

A composition comprising a pharmaceutically acceptable carrier and a compound (1):

### Claim 8 (depends on 1, 2)

A method of inhibiting the binding of a chemokine, which is MIP-1α or RANTES, to a CCR1 receptor, comprising contacting the composition of claim 1 or 2 with a cell that expresses the CCR1 receptor for a time sufficient to inhibit the binding of the chemokine to the CCR1 receptor.

### Claim 9 (depends on 1, 2)

A method of treating an inflammatory disease, comprising administering a therapeutically effective amount of the composition of claim 1 or 2 to a patient in need thereof for a time sufficient to treat the inflammatory disease.
